Microsoft Eyes Legal Action as Amazon-OpenAI Deal Threatens Azure Exclusivity 
Asian Currencies Rebound as Dollar Weakens, BOJ Holds Rates 
Gold Prices Stabilize but Head for Worst Weekly Drop in Six Years Amid Iran War Inflation Fears 
Federal Reserve Crisis: DOJ Standoff Threatens Powell's Succession and Rate Stability 
Iran-Israel War Escalates: Long-Range Missiles, Nuclear Site Strikes, and Global Energy Crisis 
U.S. Stock Futures Steady as Wall Street Retreats on Oil Volatility and Fed Rate Outlook 
Virgin Australia Adjusts Fares Amid Rising Aviation Costs and Middle East Tensions 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Micron Technology Beats Q2 Earnings Estimates, Issues Strong AI-Driven Outlook 
Apple Defies China's Smartphone Slump with Strong Early 2026 Sales 
Genel Energy Reports FY25 Net Loss Below Fears, EBITDAX Beats Forecasts 
Alibaba Bets on AI Agents to Unify Its Vast Digital Ecosystem 
Gold Prices Extend Losing Streak, On Track for Worst Weekly Loss Since 1983 
United Airlines Cuts Flights 5% Amid Soaring Fuel Costs From Iran War 
HSBC Considers Cutting 20,000 Jobs Amid AI-Driven Transformation 
Johnson & Johnson acquires Abiomed medical device technology company that develops and manufactures temporary external and implantable mechanical circulatory support devices such as the heart pump. The company invested $16.6 million in the acquisition deal.
Johnson & Johnson revealed its latest investment on Tuesday, Nov. 1, and it was described as its biggest purchase in almost six years. The buyout was a strategic move as the company is looking to bolster its cardiovascular business.
It was noted that the decision was made at a time when Johnson & Johnson was spinning off its consumer health business unit so it could focus on works related to pharmaceuticals and medical devices. The addition of Abiomed to its portfolio through the acquisition deal is expected to scale up its medical device division.
As part of the agreement, the company will pay $380 for each Abiomed share. It will also hand out another $35 per share in cash if the Danvers, Massachusetts-headquartered medical device maker achieves new commercial and clinical milestones, as per CNBC.
Abiomed is known to develop heart pumps and other technology for the treatment of coronary artery disease and heart failure. Its Impella heart pump device is typically used for patients suffering from severe coronary artery disease.
This Johnson & Johnson and Abiomed acquisition agreement is expected to be completed by early next year. Once done, it will help J&J broaden its position as a thriving cardiovascular innovator while also building its medical device segment.
“The addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech,” Johnson & Johnson’s chief executive officer, Joaquin Duato, said in a press release.
The CEO added, “We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.”
Finally, Johson & Johnson said that Abiomed will be placed under its medical technology unit but that, despite the acquisition, it will continue to operate as a standalone business.
